玮俊生物科技发盈警 预期年度净亏损不超过1300万港元 同比显著减少

Core Viewpoint - The company, Wei Jun Biotechnology (00660), expects a significant reduction in net loss for the fiscal year ending June 30, 2025, with an anticipated loss not exceeding HKD 13 million, compared to a net loss of approximately HKD 65.7 million for the fiscal year ending June 30, 2024 [1] Group 1 - The expected net loss for the fiscal year ending June 30, 2025, is projected to be less than HKD 13 million [1] - This represents a substantial decrease from the net loss of about HKD 65.7 million for the fiscal year ending June 30, 2024 [1] - The primary reason for the significant reduction in loss is attributed to a decrease in impairment losses on non-financial assets during the reporting year [1]